Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors

Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent

Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV

Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients

FDA approves Roche’s kidney inflammation drug

Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study

Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years

Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis

Enzalutamide leads to 40% lower risk of death in prostate cancer

XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting

Lundbeck and Contera Pharma join forces to advance RNA therapies for neurological disorders

Contera Pharma will receive an upfront payment and full research funding for each target under investigation

Roquette opens health and pharma solutions innovation center in Brazil

This new facility strengthens Latin America as a collaborative hub

Strides partners with Incepta to expand women's health access with WHO-prequalified contraceptive

Medroxyprogesterone acetate-SC is a three-month contraceptive that can be administered by healthcare workers or self-injected after appropriate training

Novelix signs technology transfer agreement with Germany-based GMBU for production of Astaxanthin

Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program

Biocon Biologics and Civica launch private-label Insulin glargine